{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"GroundBBreaker 301","nct_id":"NCT07836530","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=groundbbreaker-301-nct07836530. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants are randomized to receive BGB-B2033 until disease progression, unacceptable toxicity, withdrawal of consent, death, or the end of the study, whichever occurs first.","label":"BGB-B2033","type":"EXPERIMENTAL"},{"description":"Participants are randomized to receive either lenvatinib or sorafenib, selected by the investigator before treatment, until disease progression, unacceptable toxicity, withdrawal of consent, death, or the end of the study, whichever occurs first.","label":"Investigator's choice: Lenvatinib OR sorafenib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-06-21","type":"ESTIMATED"},"conditions":["Hepatocellular Carcinoma","Liver Cancer"],"enrollment":{"count":492,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"BGB-B2033","otherNames":[],"type":"DRUG"},{"name":"Lenvatinib","otherNames":["Lenvima"],"type":"DRUG"},{"name":"Sorafenib","otherNames":["Nexavar"],"type":"DRUG"}],"last_update":"2026-11-10","lead_sponsor":"BeOne Medicines","official_title":"A Randomized, Open-Label, Phase 3 Study to Investigate the Efficacy and Safety of BGB-B2033 Compared With Investigator Choice of Sorafenib or Lenvatinib in Patients With Hepatocellular Carcinoma That Progressed Upon Prior Systemic Treatment","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-09-21","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 3.5 years"}],"references":[],"start_date":{"date":"2026-10-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma","url":"https://clinicaltrials.gov/study/NCT07836530"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/groundbbreaker-301-nct07836530"}